NICE Eyes on Evidence - Issue 80 January 2016

This month in Eyes on Evidence

Oxygen therapy for acute ST-segment-elevation myocardial infarction
A randomised controlled trial in Australia found that administering inhaled oxygen did not limit damage to heart muscle and could be associated with an increase in muscle damage in people with acute ST-segment-elevation myocardial infarction.

Managing chronic rhinosinusitis in adults
A systematic review found evidence supporting daily high-volume nasal irrigation with saline and topical corticosteroid treatment as a first-line maintenance treatment for adults with chronic rhinosinusitis (symptoms for 12 weeks or longer).

Thyroid function testing in primary care
A cross-sectional study at a single UK general practice found that only 2% of people who underwent thyroid function tests in primary care had thyroid disease. The study identified specific clinical characteristics, such as hair loss or constipation, that could possibly be used to target testing at people most likely to have hypothyroidism or hyperthyroidism.

Occupational therapy for older people with stroke-related disabilities who live in care homes
A UK randomised controlled trial found that brief individualised occupational therapy delivered solely by occupational therapists had no effect on the degree of functional independence among older care home residents with stroke-related disabilities who had experienced stroke several years before.

Long-term mental health effects of bullying during adolescence
A UK prospective cohort study found that young people who experienced frequent bullying at age 13 were more likely to report depression at age 18 than those who were not bullied.

Evidence summaries from NICE’s Medicines and Prescribing Programme
NICE has recently published summaries on:
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo)
Diabetic nephropathy: blood pressure-lowering therapy
Early breast cancer: adjuvant bisphosphonate treatment beneficial in postmenopausal women